Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On track for expanded pancreatic cancer ...
A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...
The NICE committee concluded that it needed additional data on various survival endpoints and further cost-effectiveness analyses.
The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
HOUSTON, TX / ACCESS Newswire / March 4, 2026 / BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on ...
Cancer spreads (metastasizes) when tumor cells shed from a primary solid tumor (for example, in the breast) and embed in ...
(Alliance News) - Faron Pharmaceuticals Ltd shares rose over 14% on Wednesday after the Turku, Finland-based biopharma's chief executive officer said the company is in "in-depth commercial discussions ...
Researchers at Fred Hutch Cancer Center are testing whether a collaborative AI research platform can accelerate the pace of ...
Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
A study published today by the DARU Journal of Pharmaceutical Sciences reports that combining cannabidiol (CBD) with the anti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results